HIV

Simulation-Based Predictions to Support the Development of a Pediatric Fixed-Dose Combination of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumarate

2026

Authors: Waalewijn H, Bevers LAH, Lewis LL, Louey MD, Kawakatsu S, Zheng Y, Giaquinto C, Nardone A, Burger DM, ter Heine R, Colbers A, Svensson EM.

Published in: Clinical Pharmacokinetics

Barriers and facilitators to adherence of infants living with HIV in sub-Saharan Africa in an era of wide access to ART: a mixed-methods study

2026

Authors: Peay HL, Kruger S, Otwombe K, Boene H, Lain MG, Ngwenya N, Domínguez-Rodríguez S, Barnabas SL, Bingaman A, Kunene M, Giaquinto C, Henderson GE, Madiehe F,

High Early Post-Discharge Mortality and Readmission in Children Living with HIV in Sub-Saharan Africa: 30-Day Outcomes from the SUPPORT Project

2026

Authors: Kyobe S, Amorim M, Kaudha E, Sukwa N, Mwiinga C, Mumbiro V, Ngouanom MPK, Abdulkarim S, Kane A, Sumbana J, Hamusonde K, Cambaco O, Matonse C,

High prevalence of ESBL-producing bacteria isolated from rectal swabs of children living with HIV at the time of hospital discharge

2026

Authors: Sumbana J, Amorim M, Kyobe S, Mwiinga C, Ngouanom MPK, Kaudha E, Sukwa N, Mumbiro V, Kane A, Gilbert A, Tembo J, Bates M, Ballesteros A,

“Will she get better or worse at home?” A qualitative study on caregivers’ and healthcare providers’ perspectives on post-discharge mortality risk in paediatric HIV care in Mozambique

2026

Authors: Cambaco O, Amorim Moraleda M, Buck WC, Capurchande R, Ballesteros A, Kyobe S, Sacarlal J, Maixenchs M, Matonse C, Timbe E, Sumbana J, Rojo P, Cinta M, Buck WC,

Cross-network, multicentre cohort study assessing real-world pregnancy and birth outcomes following prenatal dolutegravir exposure in Europe

2026

Authors: Sconza R, Vannappagari V, Kowalska JD, Thorne C; DOLOMITE-EPPICC Study Group; DOLOMITE-NEAT ID Study Group.

Presented at: AIDS 2026

Every-8-weeks injectable cabotegravir and rilpivirine is superior to daily oral tenofovir disoproxil fumarate/ lamivudine/ dolutegravir in adolescents living with HIV in sub-Saharan Africa: LATA 96-week results

2026

Authors: Bwakura Dangarembizi M, Chappell E, Kekitiinwa AR, Kityo C, Siika A, Archary M, Jafta L, Mujuru HA, Anena LD, Nakabuye S, Kiilu C, Mngqibisa R, Akabwai G,

Sustained undetectable intact reservoir in early treated infants in Africa

2026

Authors: Reddy K, Cotugno N, Morrocchi E, Molechan C, Dominguez-Rodriguez S, Loubser S, Tiemessen CT, Barnabas S, Grazia Lain M, Otwombe K, Maiga A, Behuhuma O, Rojo P,

Sustaining advanced HIV disease care: Lessons from program integration and country experiences

2026

THRIVE Satellite Session at AIDS 2026

Organizers: Clinton Health Access Initiative, Unitaid

View presentation slides

Knowledge, Training, and Implementation Gaps in Delivery of the STOP AIDS Package for Pediatric Advanced HIV Disease: A Multi-Country Assessment

2026

Authors: Fernández-Luis S, de la Fuente L, Tusell M, Hergeth J, Prendergast AJ, Sacarlal J, Buck WC, Namusoke Magongo E, McEneaney P, Collins IJ, Schindele A, Evans C,

Demographic, laboratory and clinical characteristics and outcomes of seriously ill hospitalized Mozambican children with advanced HIV disease

2026

Authors: Mavume C, Fernández-Luis S, Schindele A, Salimo A, Cassam Y, Joaquim W, Maieca A, Beca L, Macassa E, Aguacheiro S, Liasse N, Martins L, Machava S,

Uncovering the gaps: a mixed methods exploration of barriers to STOP-AIDS implementation

2026

Authors: Chingombe I, Mangwende M, Mapfumo HF, Madhuyu L, Ndlovu N, Chidhanguro D, Tavengwa N, Fernández-Luis S, Tusell M, Langhaug L, Muchekeza M, Nyachowe C, Chikunya J,

Addressing gaps in provider-initiated testing and counseling and early infant diagnosis to optimize inpatient pediatric advanced HIV disease care in Mozambican hospitals

2026

Authors: Salimo A, Buck WC, Schindele A, Fernández-Luis S, Gastesi I, Mavume C, Cassam Y, Joaquim W, Maieca A, Beca L, Macassa E, Aguacheiro S, Liasse N,

Implementation of the advanced HIV disease care package for hospitalized children: baseline results from a Quality Improvement initiative in Mozambique

2026

Authors: Cassam Y, Schindele A, Fernández-Luis S, Gastesi I, Salimo A, Joaquim W, Maieca A, Beca L, Mavume C, Macassa E, Aguacheiro S, Liasse N, Martins L,

Prevalence of Advanced HIV Disease (AHD) and missed screening opportunities among Children and Adolescents living with HIV (CALHIV) in Uganda

2026

Authors: Mulowoza C, Crichton S, Le Prevost M, Kalibbala D, Fernandez-Luis S, Fuente-Soro L, Kayaga J, Nyamaizi P, Kiweewa F, Collins IJ, Magongo EN.

Presented at: International Workshop on Pediatrics and HIV

“Will she get better or worse at home?” A qualitative study on caregivers’ and healthcare providers’ perspectives on post-discharge mortality risk in paediatric HIV care in Mozambique

2026

Authors: Cambaco O, Amorim M, Moraleda C, Buck WC, Capurchande R, Ballesteros Á, Kyobe S, Sacarlal J, Maixenchs M, Matonse C, Timbe E, Sumbana J, Rojo P,

T-cell subsets, T-cell receptor repertoire and HIV-1 virological reservoir in children initiating first-line dolutegravir versus standard-of-care ART: results from the ODYSSEY trial

2026

Authors: Gärtner K, Wyncoll J, Hammer ASB, Rattenborg MN, Adams S, Byott M, Alber D, Botha JC, Kekitiinwa AR, Kityo C, Bamford A, Bwakura-Dangarembizi M, Violari A,

HIV-1 resistance in children aged 2 to <15 years receiving DTG/3TC or DTG+2NRTI: results from the D3/PENTA-21 trial over 96 weeks

2026

Authors: Botha JC, Byott M, Chen W, Grant P, Spyer MJ, Wang R, Boles J, Gärtner K, Kamrunnahar K, Archary M, Violari A, Variava E, Cressey T,

Predictors of viral non-suppression in children living with HIV initiating second-line antiretroviral therapy in the ODYSSEY and CHAPAS-4 trials

2026

Authors: Amuge P, Wyncoll J, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kityo CM, Chabala C, Nyathi M, Nduna B, Musoke P, Srirompotong U, Violari A, Archary M,

Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial

2026

Authors: Moraleda C, Tagarro A, Domínguez-Rodríguez S, Musiime V, Mujuru H, Chabala C, Mvalo T, Iroh-Tam PY, Bramugy J, Madrid L, Sacarlal J, Passanduca A, Sidat M,

Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial

2026

Authors: Mujuru HA, White E, Kekitiinwa AR, Lugemwa A, Kityo C, Violari A, Ahimbisibwe GM, Variava E, Archary M, Cotton M, Ounchanum P, Puthanakit T, Kanjanavanit S,

Exploring the pharmacokinetic mechanisms that affect bictegravir exposure during pregnancy

2026

Authors: van der Wekken-Pas L, Hidalgo-Tenorio C, Rockstroh JK, van Bremen K, Richel O, Molto J, Lambert JS, de Kanter C, Konopnicki D, Burger D, Colbers A.

Dolutegravir as first- or second-line treatment for children living with HIV: 240-week follow-up of the ODYSSEY randomised trial

2026

Authors: Mujuru HA, White E, Kekitiinwa AR, Lugemwa A, Kityo C, Violari A, Ahimbisibwe GM, Variava E, Archary M, Cotton M, Ounchanum P, Puthanakit T, Kanjanavanit S,

Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial

2026

Authors: Wyncoll J, Kamolrattana R, Archary M, Mujuru HA, Kekitiinwa AR, Violari A, Na-Rajsima S, Lugemwa A, Variava E, Cotton M, Kityo CM, Königs C, Behuhuma NO,

DTG/3TC is non-inferior to DTG-based 3-drug ART in children with HIV: D3/Penta 21 week-96 results

2026

Authors: Turkova A, Chan MK, Kekitiinwa AR, Mutuluuza CK, Musoke P, Cressey TR, Violari A, Archary M, Variava E, Rojo P, Welch SB, Thomason MJ, Giaquinto C, Ford D.

Empirical treatment against cytomegalovirus and tuberculosis in severe pneumonia in HIV-infected infants: a randomized controlled clinical trial

2026

Authors: Moraleda C, Rojo P, Dominguez S, Dominguez S, Buck CW, Musiime V, Mujuru HA, Chabala C, Mvalo T, Bramugy J, Madrid L, Sacarlal J, Ghambi L, Fernandez-Luis S,

Sex matters: A Bayesian approach to analyzing sex differences in an African pediatric cohort

2026

Authors: Gastesi Orbegozo I, Ballesteros A, Barnabas S, Barnabas S, Behuhuma O, Lain MG, Nhampossa T, Otwombe K, Rossi P, Giaquinto C, Kuhn L, Reddy K, Cotugno N,

Prime-boost HIVIS DNA and MVA-CMDR regimen induces robust Env and Gag antibody responses in youth living with HIV

2026

Authors: Kim J, Slike B, McCarragher C, Nguyen P, Metzger L, Moreland S, Pinyakorn S, Schluck G, Krebs S, Rao M, Palma P, Robb M; on behalf of the RV534 study group.M,

HIV-1 DNA dynamics with HIVIS DNA/MVA-CDMR vaccinations +/-TLR4 Agonist: the HVRRICANE trial

2026

Authors: Dhummakupt A, Szewczyk J, Barnabas S, Cotton M, Gorelick R, Pinyakorn S, Turk E, DeSouza M, Cotugno N, Maldarelli F, Palma P, Spiegel H, Robb M, Persaud D;

Pharmacokinetics of a Novel Dose Ratio of DTG/FTC/TAF for African Children with HIV (UNIVERSAL1)

2026

Authors: Kamphuis AEM, Mujuru HA, Bwakura-Dangarembizi MF, Kisitu GP, Matovu F, Kaudha E, Mulindwa A, Jacobs TG, Salvadori N, Than-in-at K, Cressey TR, Nardone A, Lallemant M, Burger DM,

SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistance

2026

Authors: Grasa C, Salvadori N, Nardone A, Than-in-at K, Koblansky A, Parry C, Thakkar N, Wang M, Giaquinto C, Rojo P & Cressey RT

Published in: BMC Infectious Diseases

Dosing of ritonavir-boosted darunavir for treatment of HIV in pregnancy

2026

Authors: Sconza R, Taylor GP, Ene L, Kahlert C, van der Wekken-Pas L, Renaud F, Thorne C, Townsend CL.

Published in: AIDS

Intentions and attitudes of caregivers towards enrolment of their children and adolescents living with HIV into remission trials involving analytic treatment interruption

2026

Authors: Peay HL, Otwombe K, Barnabas S, Barrios-Tascon A, Lain MG, Nhampossa T, Rutebarika D, Jupimai T, Archary M, Maiga A-I, Violari A, Spyer MJ, Reddy K, Palma P,

Integrating life course perspectives into research involving people living with perinatally acquired HIV

2026

Authors: Toledo G, Le Prevost M, Judd A, Collins IJ.

Published in: BMC Global and Public Health

Perinatal HIV exposure is associated with long-term alterations in immune marker levels in children

2026

Authors: Avendaño-Ortiz J, Ventosa-Cubillo J, Rodríguez-Jiménez C, Morales-Pérez D, Muñoz-Hernández R, Pavía-Ruz N, Navarro ML, Holguín Á.

Published in: Journal of Infection and Public Health

Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial

2026

Authors: Turkova A, White E, Violari A, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kaudha E, Na-Rajsima S, Ahimbisibwe GM, Variavae E, Archary M, Akhalwaya Y, Puthanakit T,

Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

2026

Authors: Anena D, Chappell E, Nazzinda R, Kiilu C, Chitsamatanga M, Arumugam T, Green A, Mutuluuza CK, Bwakura-Dangarembizi M, Siika A, Archary M, Jafta L, Namukwaya S,

Late diagnosis of paediatric HIV infection in high-income countries: Lessons from the HIV Perinatal Virtual Clinic

2025

Authors: Curto C, Tritzali M, Bamford A, Bailey AC, Lyall EGH, Mackie NE, Tickner N, Foster C; on behalf of the PVC.

Published in: HIV Medicine

Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025

2025

Authors: Ambrosioni J, Levi LI, Alagaratnam J, Sempere A, Mastrangelo A, Paioni P, Mussini C, Marzolini C, Nielsen SD, Béguelin C, Welch S, Koval A, Mendao L,

Changes in body mass index in children and adolescents living with HIV in Europe and Thailand starting dolutegravir 

2025

Authors: Edgar K, The Epidemiology of Pregnancy and Paediatric Infections International Cohort Collaboration (EPPICC) study group

Published in: Open Forum Infectious Diseases

Effectiveness and safety of tenofovir alafenamide fumarate–based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe

2025

Authors: Chappell E, The European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) Study Group

Published in: International Journal of Antimicrobial Agents

Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial

2025

Authors: Bevers LAH, Toledo G, Kisekka M, Kaudha E, Ahimbisibwe GM, Deprez I, Arumugan T, Variava E, Violari A, White I, Bbuye D, Nanduudu A, Mulwanyi E, Amuge P,

Adolescents in phase 3 HIV clinical trials

2025

Authors: Foster C, Ruel T, Ford D, Turner RM, Archary M, Rojo P, Gibb D; Penta-IMPAACT.

Published in: The Lancet Child & Adolescent Health

Research gaps for children who are HIV-exposed but uninfected: outcomes of a research prioritisation workshop

2025

Authors: Wedderburn CJ, Evans C, Abrams EJ, Bamford A, Bekker A, Bunders MJ, Epalza C, Foster C, Frigati L, Goetghebuer T, John-Stewart G, Kahlert CR, Moraleda C, Musiime V,

Weight gain on tenofovir alafenamide fumarate‐based therapy compared to tenofovir disoproxil fumarate‐ and abacavir‐based therapy in children and young people living with HIV in Europe

2025

Authors: The European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) Study Group

Published in: HIV Medicine

Mortality rates and associated factors among people living with perinatally acquired HIV in Europe and Thailand

2025

Authors: O’Rourke J, Chappell E, Collins IJ, Crichton S, Ene L, Le Coeur S, Le Prevost M, Marques L, Naver L, Noguera-Julian A, Pluta M, Prime K,

Growth trajectories before and after switching to dolutegravir in children living with HIV in the ODYSSEY trial

2025

Authors: Chan MK, Crichton S, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kityo CM, Ahimbisibwe GM, Variava E, Violari A, Cotton M, Archary M, Cressey TR, Puthanakit T,

Pregnancies among adolescents and young women on dolutegravir vs standard-of-care in the ODYSSEY trial and effects of the dolutegravir neural tube defect safety alert

2025

Authors: Ahimbisibwe G, Wyncoll J, Mngqibisa R, White E, Bwakura-Dangarembizi M, Kekitiinwa AR, Lugemwa A, Kityo CM, Variava E, Liberty A, Kataike H, Ngampiyaskul C, Cotton MF,

Growth outcomes in children living with HIV in Europe and Thailand before and after starting dolutegravir

2025

Authors: Edgar K, Scott K, Castro H, O’Rourke J, Ene L, Galli L, Goetghebuer T, Henegar C, Hoffmann TU, Koenigs C, Marczyńska M, Naver L, Noguera-Julian A,

Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial

2025

Authors: Wyncoll J, Archary M, Kamolrattana R, Mujuru HA, Kekitiinwa AR, Violari A, Na-Rajsima S, Lugemwa A, Variava E, Cotton M, Kityo CM, Puthanakit T, Königs C,

123456789